We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Pegylated liposomal doxorubicin in malignant pleural mesothelioma: a possible guardian for long-term survival.
- Authors
Zarogoulidis, Paul; Mavroudi, Maria; Porpodis, Konstantinos; Domvri, Kalliopi; Sakkas, Antonios; Machairiotis, Nikolaos; Stylianaki, Aikaterini; Tsiotsios, Anastasios; Courcoutsakis, Nikolaos; Zarogoulidis, Konstantinos
- Abstract
Malignant pleural mesothelioma is a rare and aggressive malignancy of the pleura correlated with exposure to asbestos, with a medium survival of 11-12 months after diagnosis. A case of a 67-year-old male who had previously worked in the asbestos industry and is a current smoker is reported. The computed tomography evaluation revealed a right pleural mass with pleural thickening, and the pleural biopsy confirmed a diagnosis of malignant pleural mesothelioma. He was treated with chemotherapy consisting of etoposide, paclitaxel, and pegylated liposomal doxorubicin hydrochloride. After completion of chemotherapy, radiologic evaluation confirmed a reduction of pleural thickening and improvement in his symptoms. A complete presentation of each drug formulation and characteristics are also included in this paper. The patient's follow-up is continuing, and computed tomography reveals stable disease 9 years after initial examination.
- Subjects
PLEURA cancer; MESOTHELIOMA; ASBESTOS -- Risk factors; PLEURAL effusions; CANCER chemotherapy; ETOPOSIDE; PACLITAXEL; CANCER treatment
- Publication
OncoTargets & Therapy, 2012, Vol 5, p231
- ISSN
1178-6930
- Publication type
Article
- DOI
10.2147/OTT.S36915